Clinical Trial Update: BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of BCX-1777 in patients with refractory cutaneous T-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• BCX-1777 (BCX-1777)

Snippet

Sponsor: BioCryst Pharmaceuticals | Conditions: Lymphoma | Phase 1, Phase 2 | Status: COMPLETED